Compare PRAX & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | KNX |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 7.0B |
| IPO Year | 2020 | 2010 |
| Metric | PRAX | KNX |
|---|---|---|
| Price | $302.98 | $52.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 18 |
| Target Price | ★ $572.13 | $60.50 |
| AVG Volume (30 Days) | 325.2K | ★ 2.6M |
| Earning Date | 05-12-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 1.29% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.41 |
| Revenue | N/A | ★ $7,469,689,000.00 |
| Revenue This Year | N/A | $5.92 |
| Revenue Next Year | $6,395.88 | $7.91 |
| P/E Ratio | ★ N/A | $135.80 |
| Revenue Growth | N/A | ★ 0.80 |
| 52 Week Low | $26.70 | $36.69 |
| 52 Week High | $354.87 | $64.10 |
| Indicator | PRAX | KNX |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 34.17 |
| Support Level | $290.36 | $41.21 |
| Resistance Level | $322.32 | $54.03 |
| Average True Range (ATR) | 16.79 | 2.52 |
| MACD | -4.88 | -1.04 |
| Stochastic Oscillator | 25.06 | 0.17 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.